argenx Halts Phase 3 Trial for Sjögren’s Disease Treatment

Key Facts

argenx announced the discontinuation of its Phase 3 trial evaluating its treatment for Sjögren’s disease. According to Investing.com, the decision follows an internal review or interim analysis of the clinical trial's progress.

The halt of a Phase 3 trial represents a significant setback for the company's drug development pipeline, typically resulting in downward pressure on investor sentiment. Specific details regarding the clinical failure were not elaborated upon in the brief update provided by the company.